ClinicalTrials.gg
CompletedNCT07656714Updated Jun 18, 2026

HFCWO Vest Plus Mechanical Cough Assist Versus Cough Assist Alone on Respiratory Infections in ALS: a Pilot Trial

An interventional study of High-frequency chest wall oscillation (HFCWO) vest and Mechanical cough assist in Amyotrophic Lateral Sclerosis and Respiratory Infection, sponsored by Hospital Universitario Virgen Macarena. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Hospital Universitario Virgen Macarena · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 5 years 2 months after the study started (first participant enrolled Apr 2021, registered Jun 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain — 11 open to participants now, 16 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Spain.

Enrollment
48th of 51
14 · median 227
Started
2021
with 11 others
No phase
6 of 56
2 open now
Registered
55th of 56
by date

Among the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain, this one is the 48th largest by enrollment of the 51 interventional ones that give a count, is one of 12 that started in 2021, is one of 6 with no phase, and was the 55th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

11 of the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain, or all of them as a file.
02

Study summary

This pilot randomised single-blind trial evaluated whether adding high-frequency chest wall oscillation (HFCWO) via chest vest (ComfortCough II) to mechanical cough assist improves respiratory outcomes and reduces respiratory infections and hospital admissions compared to mechanical cough assist alone in patients with amyotrophic lateral sclerosis (ALS) receiving non-invasive ventilation.

Read the detailed description

Patients with amyotrophic lateral sclerosis (ALS) receiving non-invasive ventilation (NIV) at the Multidisciplinary ALS Unit of Hospital Universitario Virgen Macarena (Seville, Spain) were randomised to two parallel groups. The experimental group received high-frequency chest wall oscillation (HFCWO) via chest vest (ComfortCough II/CC20) combined with mechanical cough assist, while the control group received mechanical cough assist alone. The intervention period lasted 3 months, followed by 3 months of follow-up. Primary outcomes included respiratory infections and hospital admissions. Secondary outcomes included respiratory function, quality of life, sleep quality, and secretion clearance capacity. The study was approved by the Ethics Committee of Hospital Universitario Virgen Macarena - Virgen del Rocío (code 2020-01) and sponsored by FISEVI (Fundación Pública Andaluza para la Investigación Biosanitaria de Andalucía).

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
  • Respiratory Infection

Keywords

  • Amyotrophic Lateral Sclerosis High-frequency chest wall oscillation Mechanical cough assist Respiratory infections Secretion clearance ALS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed diagnosis of ALS according to the Revised El Escorial criteria
  2. Under follow-up at the Multidisciplinary ALS Unit of Hospital Universitario Virgen Macarena
  3. Age between 18 and 90 years
  4. Peak cough flow less than 270 L/min or forced vital capacity (FVC) less than 80% of predicted
  5. Ability to travel to the Neurolab centre

Exclusion criteria

exclusion criteria:

  1. Need for invasive mechanical ventilation
  2. Total dependence on non-invasive ventilation (NIV)
  3. Severe bulbar involvement
  4. Cognitive impairment
  5. Comorbidities incompatible with the intervention: pregnancy, rib fractures, known risk of pneumothorax or pneumomediastinum, cerebrospinal fluid fistula, pneumocephalus, or recent barotrauma
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    arm label Experimental: HFCWO plus mechanical cough assist

    Patients received high-frequency chest wall oscillation via chest vest (ComfortCough II) combined with mechanical cough assist for 3 months followed by 3 months follow-up.

    Device: High-frequency chest wall oscillation (HFCWO) vest · Device: Mechanical cough assist

  • Active comparator
    Control: Mechanical cough assist alone

    Patients received mechanical cough assist alone for 3 months followed by 3 months follow-up.

    Device: Mechanical cough assist

Interventions

  • DeviceHigh-frequency chest wall oscillation (HFCWO) vest

    Chest wall oscillation vest delivering high-frequency vibrations to mobilise secretions, used in addition to mechanical cough assist device during the 3-month intervention period.

    Also known as: ComfortCough II , CC20

  • DeviceMechanical cough assist

    Mechanical insufflation-exsufflation device used alone for airway secretion clearance during the 3-month intervention period.

    Also known as: Cough assist device

06

What researchers measure

Primary outcomes

  1. Number of respiratory infections

    Number of respiratory infections requiring antibiotic treatment during the study period

    Time frame: 6 months (3 months intervention plus 3 months follow-up)

Secondary outcomes

  1. Number of hospital admissions

    Number of hospital admissions due to respiratory causes during the study period

    Time frame: 6 months (3 months intervention plus 3 months follow-up)

Other outcomes

  1. Forced Vital Capacity (FVC)

    Change in forced vital capacity percentage from baseline

    Time frame: 6 months

  2. Peak Cough Flow (PCF)

    Change in peak cough flow from baseline

    Time frame: 6 months

  3. Gait analysis

    Change in gait parameters assessed by GAITRite electronic walkway system and correlation with respiratory function (FVC)

    Time frame: 6 months

07

Study locations

1 site
  • Hospital Universitario Virgen Macarena
    Seville, Andalusia 41009, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Nov 2023, 30 months.

Of 134 non-industry interventional studies with no phase under Amyotrophic Lateral Sclerosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's 30 months is below that.

Counting every sponsor, half of 154 studies reached it within 35 months; a quarter within 23 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 18, 2026
StartActual
Apr 15, 2021
Primary completionActual
Nov 2, 2023
CompletionActual
Apr 27, 2025
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07656714
Lead sponsor
Hospital Universitario Virgen Macarena
Responsible party
Sponsor
First posted
Jun 18, 2026
Start date
Apr 15, 2021
Primary completion
Nov 2, 2023
Completion
Apr 27, 2025
Last update
Jun 18, 2026

Study contacts

Concepcion Romero Muñoz
principal investigator · Hospital Universitario Virgen Macarena

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion